{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-046091","form_type":"8-K/A","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.803100+00:00","generated_at":"2026-06-24T01:23:15.457560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OptimizeRx Q2 revenue up 3% to $14M, GAAP net loss of $3.9M, cuts FY 2022 outlook","bullets":["GAAP net loss of $3.9M ($0.21/sh) vs prior-year net income of $0.4M ($0.02/sh).","Non-GAAP net income of $0.7M ($0.04/sh) down from $1.8M ($0.10/sh) a year ago.","Gross margin improved to 64% from 59%; revenue of $14.0M, +3% YoY.","FY 2022 revenue guidance lowered to $62-68M (1-11% growth); gross margin 59-62%.","Share repurchase program authorized up to $20M; 232,745 shares bought at avg $23.02."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-046091","json":"https://secwatch.observer/filing/0001213900-22-046091.json","markdown":"https://secwatch.observer/filing/0001213900-22-046091.md","text":"https://secwatch.observer/filing/0001213900-22-046091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/0001213900-22-046091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/ea164114-8ka1_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:23:15.457560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}